File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Outcome of hematopoietic stem cell transplantation In refractory/relapsed infant leukemia
Title | Outcome of hematopoietic stem cell transplantation In refractory/relapsed infant leukemia |
---|---|
Authors | |
Keywords | Medical sciences Oncology medical sciences Pediatrics |
Issue Date | 2013 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/ |
Citation | The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 n. S3, p. 73, abstract no. P-0078 How to Cite? |
Abstract | PURPOSE/OBJECTIVE: Refractory/relapsed infant leukemia has an extremely poor prognosis. Whether hematopoietic stem cell transplantation (HSCT) can improve their outcome remains controversial. We reviewed our experience of HSCT on this group of patients. MATERIALS AND METHODS: This is a retrospective chart review on our HSCT patients’ cohort from Jan 1, 1995 to Dec 31, 2007. The indexed cases were identified from our HSCT electronic database from 1992 to 2007. RESULTS: Among >200 HSCT performed within this period, 8 patients with refractory/relapsed infant leukemia who underwent allogeneic HSCT were identified. Four patients had acute myeloid leukemia (AML); 2 had acute lymphoblastic leukemia (ALL); 1had juvenile myelomonocytic leukemia (JMML); and 1 had mixed lineage leukemia. Four patients had an initial white blood cell count >50_109/L, and 2 patients had cytogenetically detectable MLL rearrangement. For donor sources at first transplant, they were unrelated cord blood (n ? 1), unrelated bone marrow (BM, n ? 1) or related BM/peripheral blood stem cells (n ? 4). Three received busulphan/cyclophosphamide (AML) and one with busulphan/cyclophosphamide/melphalan (JMML) as conditioning and the other 4 had fludarabine based regimen with low dose irradiation. Seven patients achieved neutrophil engraftment at a median of 17 days (range: 13-22 days). Four patients relapsed after HSCT and 2 of them had upfront related HSCT. Despite second HSCT done in 2/4, all 4 of them died. Six patients experienced Grade III-IV acute graft versus host disease, and 5 (including the 2 with second transplant) developed various degree of hepatic venous-occlusive disease (VOD). Three patients (1ALL, 1AML & 1JMML) survived at 3, 8.8, and 13.8 years. The overall survival at 3 years was 37.5 +/- 17.1%. CONCLUSIONS: Despite having very poor prognosis, selected infants with refractory/relapsed leukemia could still be salvaged by allogeneic HSCT. We noted a high VOD and GvHD in our cohort so appropriate conditioning regimens should be adopted in the future. |
Description | This journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013 Poster Presentation in Poster Session - Myeloid leukemias: abstract no. P-0078 |
Persistent Identifier | http://hdl.handle.net/10722/193635 |
ISSN | 2023 Impact Factor: 2.4 2023 SCImago Journal Rankings: 0.992 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Xiong, H | en_US |
dc.contributor.author | Ha, SY | en_US |
dc.contributor.author | Chiang, A | en_US |
dc.contributor.author | Cheuk, DKL | en_US |
dc.contributor.author | Li, H | en_US |
dc.contributor.author | Chan, G | en_US |
dc.date.accessioned | 2014-01-20T05:12:14Z | - |
dc.date.available | 2014-01-20T05:12:14Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 n. S3, p. 73, abstract no. P-0078 | en_US |
dc.identifier.issn | 1545-5009 | - |
dc.identifier.uri | http://hdl.handle.net/10722/193635 | - |
dc.description | This journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013 | - |
dc.description | Poster Presentation in Poster Session - Myeloid leukemias: abstract no. P-0078 | - |
dc.description.abstract | PURPOSE/OBJECTIVE: Refractory/relapsed infant leukemia has an extremely poor prognosis. Whether hematopoietic stem cell transplantation (HSCT) can improve their outcome remains controversial. We reviewed our experience of HSCT on this group of patients. MATERIALS AND METHODS: This is a retrospective chart review on our HSCT patients’ cohort from Jan 1, 1995 to Dec 31, 2007. The indexed cases were identified from our HSCT electronic database from 1992 to 2007. RESULTS: Among >200 HSCT performed within this period, 8 patients with refractory/relapsed infant leukemia who underwent allogeneic HSCT were identified. Four patients had acute myeloid leukemia (AML); 2 had acute lymphoblastic leukemia (ALL); 1had juvenile myelomonocytic leukemia (JMML); and 1 had mixed lineage leukemia. Four patients had an initial white blood cell count >50_109/L, and 2 patients had cytogenetically detectable MLL rearrangement. For donor sources at first transplant, they were unrelated cord blood (n ? 1), unrelated bone marrow (BM, n ? 1) or related BM/peripheral blood stem cells (n ? 4). Three received busulphan/cyclophosphamide (AML) and one with busulphan/cyclophosphamide/melphalan (JMML) as conditioning and the other 4 had fludarabine based regimen with low dose irradiation. Seven patients achieved neutrophil engraftment at a median of 17 days (range: 13-22 days). Four patients relapsed after HSCT and 2 of them had upfront related HSCT. Despite second HSCT done in 2/4, all 4 of them died. Six patients experienced Grade III-IV acute graft versus host disease, and 5 (including the 2 with second transplant) developed various degree of hepatic venous-occlusive disease (VOD). Three patients (1ALL, 1AML & 1JMML) survived at 3, 8.8, and 13.8 years. The overall survival at 3 years was 37.5 +/- 17.1%. CONCLUSIONS: Despite having very poor prognosis, selected infants with refractory/relapsed leukemia could still be salvaged by allogeneic HSCT. We noted a high VOD and GvHD in our cohort so appropriate conditioning regimens should be adopted in the future. | - |
dc.language | eng | en_US |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/ | - |
dc.relation.ispartof | Pediatric Blood & Cancer | en_US |
dc.rights | Pediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc. | - |
dc.subject | Medical sciences | - |
dc.subject | Oncology medical sciences | - |
dc.subject | Pediatrics | - |
dc.title | Outcome of hematopoietic stem cell transplantation In refractory/relapsed infant leukemia | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Ha, SY: syha@hku.hk | en_US |
dc.identifier.email | Chiang, A: chiangak@hku.hk | en_US |
dc.identifier.email | Cheuk, DKL: klcheuk@hkucc.hku.hk | en_US |
dc.identifier.email | Chan, G: gcfchan@hku.hk | en_US |
dc.identifier.authority | Chiang, A=rp00403 | en_US |
dc.identifier.authority | Chan, G=rp00431 | en_US |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1002/pbc.24719 | - |
dc.identifier.hkuros | 227213 | en_US |
dc.identifier.volume | 60 | - |
dc.identifier.issue | suppl. 3 | - |
dc.identifier.spage | 73, abstract no. P-0078 | - |
dc.identifier.epage | 73, abstract no. P-0078 | - |
dc.publisher.place | United States | - |
dc.customcontrol.immutable | sml 140710 | - |
dc.identifier.issnl | 1545-5009 | - |